Načítá se...
The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis
BACKGROUND: A combination of temozolomide (TMZ) and radiotherapy and subsequent adjuvant chemotherapy is the gold standard of treatment for glioblastoma (GB). Bevacizumab (BEV), a humanized monoclonal antibody that blocks the effects of vascular endothelial growth factor A, has produced impressive r...
Uloženo v:
| Vydáno v: | Onco Targets Ther |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6016281/ https://ncbi.nlm.nih.gov/pubmed/29950856 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S156723 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|